Medicare Part D

Medicare Part D is the federal government’s program designed to provide outpatient prescription drug insurance to Medicare-eligible individuals, primarily through private insurance companies that contract with the Centers for Medicare & Medicaid Services (CMS). Within the landscape of human resources and employee benefits administration, this program serves as the benchmark against which employer-sponsored prescription drug plans must be measured to determine "creditable coverage" status. Organizations that offer health benefits are required by law to evaluate whether their pharmacy benefits are actuarially equivalent to or better than the standard benefit offered under the federal program. This evaluation dictates the regulatory disclosure requirements the organization must fulfill annually to both its plan participants and the federal government.

The Regulatory Framework of Prescription Drug Coverage

Understanding the intersection of federal benefits and employer-sponsored health plans requires a detailed look at the Medicare Modernization Act (MMA) of 2003. This legislation fundamentally changed how organizations manage retiree and active employee pharmacy benefits. For those overseeing benefit compliance, the primary focus is not the administration of the federal program itself, but rather the synchronization of organizational plans with the federal standards.

The program is divided into various phases of coverage: the initial deductible, the initial coverage phase, and the catastrophic coverage phase. Historically, a "coverage gap" or "donut hole" existed, but recent legislative overhauls have significantly restructured these tiers. In 2026, the structure has moved toward a more streamlined model with lower out-of-pocket maximums for beneficiaries.

The Standard Benefit Benchmark

To remain compliant, an organization must understand the "Defined Standard Benefit." This is the minimum level of coverage set by CMS each year. If an employer's plan does not meet this financial threshold, it is deemed "non-creditable." This distinction is critical because individuals who go without creditable coverage for 63 days or more after becoming eligible for the federal program may face permanent late enrollment penalties.

According to data from the Kaiser Family Foundation (KFF), total enrollment in the federal prescription drug program reached 56.1 million beneficiaries as of early 2026, a steady increase from 54.6 million in 2025 (Source: KFF 2026 Analysis). This growth underscores the importance of employer-sponsored plans accurately communicating how their benefits interact with this expanding federal program.

Creditable vs. Non-Creditable Coverage: The Critical Distinction

The determination of whether a group health plan’s prescription drug coverage is "creditable" is perhaps the most significant recurring task for those managing health benefits. Creditable coverage means that the employer-sponsored plan is expected to pay, on average, at least as much as the standard medicare part D plan would pay.

Simplified Determination vs. Actuarial Equivalence

CMS provides two primary methods for determining creditability:

• Simplified Determination - A set of criteria based on the plan's design (e.g., whether the plan has no annual maximum benefit or is designed to pay at least 60% of prescription drug expenses).

• Actuarial Equivalence - A more complex calculation typically performed by an actuary to prove the plan’s value mathematically.

Recent updates under the Inflation Reduction Act (IRA) have necessitated changes in how these determinations are made. For the 2026 calendar year, CMS finalized a revised simplified determination method. Under this new standard, a plan is generally considered creditable if it is designed to pay, on average, at least 72% of participants' prescription drug expenses (Source: Risk Strategies Compliance Update). This is a notable increase from the previous 60% threshold, reflecting the richer benefits now provided by the federal government.

Mandatory Disclosure Requirements

Organizations offering prescription drug coverage to Medicare-eligible individuals (which includes active employees, retirees, and dependents) face two distinct annual disclosure mandates.

1. Disclosure to Plan Participants

Organizations must provide a "Notice of Creditable Coverage" or "Notice of Non-Creditable Coverage" to all Medicare-eligible individuals covered under the plan. This must occur:

• Prior to October 15th each year (the start of the Annual Election Period).

• Prior to an individual’s Initial Enrollment Period.

• Prior to the effective date of coverage for any Medicare-eligible individual.

• Whenever the plan’s creditability status changes.

• Upon request.

While the notice does not need to be a standalone mailing, it can be included in open enrollment materials, it must be prominent. Many organizations choose to send it to all plan participants to avoid the administrative burden of tracking which employees or spouses have reached age 65 or have a qualifying disability.

2. Disclosure to CMS

The second mandate is an electronic filing with CMS. This filing confirms the creditability status of the plan for the prior year. This must be completed within 60 days of the beginning of each plan year. For a calendar-year plan starting January 1st, this deadline is typically March 1st.

Failure to complete this filing does not necessarily result in a direct fine, but it can lead to complications during Department of Labor (DOL) audits or when seeking the Retiree Drug Subsidy (RDS).

The Impact of the Inflation Reduction Act on Employer Plans

The landscape of prescription drug benefits has been fundamentally altered by the Inflation Reduction Act. One of the most significant changes for beneficiaries is the implementation of a hard cap on out-of-pocket costs. In 2025, this cap was set at $2,000, and for 2026, the out-of-pocket limit was adjusted to $2,100 (Source: CMS Technical Specifications).

Because the federal program has become significantly more generous, many employer plans that were previously considered "creditable" may no longer meet the threshold. If a private plan has a high deductible or a high coinsurance rate that allows a participant's out-of-pocket costs to exceed $2,100, that plan might be deemed non-creditable in 2026. This forces a strategic choice: either enhance the plan's benefits to maintain a creditable status or inform employees that the plan is non-creditable.

Coordination of Benefits: Who Pays First?

For active employees over age 65, the question of "primary" versus "secondary" coverage is a common source of confusion. The rules for coordination of benefits are determined by the size of the employer.

Working Aged Rules

• Employers with 20 or More Employees - The employer-sponsored group health plan is primary, and medicare part D is secondary. In this scenario, the employer plan pays first, and the federal program may cover remaining costs if the individual is enrolled.

• Employers with Fewer than 20 Employees - Medicare is the primary payer, and the employer plan is secondary.

For retirees, Medicare is almost always the primary payer. Organizations managing retiree health plans often use "Wrap" programs or "Employer Group Waiver Plans" (EGWPs) to supplement the federal coverage.

Retiree Drug Subsidy (RDS) vs. Employer Group Waiver Plans (EGWP)

Historically, many large organizations maintained their own retiree drug plans and received a tax-free subsidy from the government to encourage them to keep those plans in place. This is known as the Retiree Drug Subsidy (RDS).

However, the financial appeal of the RDS has waned. In 2019, only about 2.3% of Medicare beneficiaries obtained coverage through employer-sponsored plans, receiving the RDS (Source: MedPAC Report). By 2026, many organizations will have transitioned to EGWPs. An EGWP (often pronounced "egg-whip") is a private medicare part D plan designed specifically for an employer’s retirees. This allows the organization to outsource the administration and compliance of the drug benefit to a private insurer while still providing a customized benefit level for their former employees.

Financial Considerations: Premiums and Stabilization

The cost of prescription drug coverage is a primary concern for benefits budget planning. The federal government has introduced a premium stabilization program to prevent drastic spikes in costs for insurers and, by extension, the employers who contract with them.

For the 2026 plan year, the national base beneficiary premium is projected to be $38.99 per month, a controlled increase from $36.78 in 2025 (Source: Medicare Resources). CMS has capped premium increases for participating plans at $50 per month for 2026 to ensure market stability following the massive structural changes of the IRA.

For organizations, these premium trends influence the "Premium Contribution" strategy. If the cost of the employer-sponsored drug plan rises faster than the federal benchmark, employees may find more value in dropping the employer plan and enrolling in a standalone medicare part D plan.

Enrollment Shifts and Market Trends

The market is seeing a notable shift in how beneficiaries access their drug benefits. While Medicare Advantage (Part C) plans that include drug coverage (MA-PDs) remain popular, there was a recorded shift in 2026.

Data shows that while enrollment in group MA-PDs declined for the first time since 2010 (dropping by 1.2 million), enrollment in group stand-alone prescription drug plans (PDPs) increased by 1.2 million (Source: KFF 2026 Enrollment Data). This suggests that more organizations are moving away from integrated Advantage plans for their retirees in favor of standalone drug coverage coupled with traditional Medicare or a supplemental plan.

Compliance Calendar and Best Practices

To avoid regulatory pitfalls, organizations should adhere to a strict compliance calendar regarding federal drug benefit standards.

Documenting the Process

Maintaining a "Compliance Binder" is a recommended best practice. This binder should contain:

• A copy of the annual creditability determination (including actuary reports if applicable).

• Evidence of the date and method of distribution for participant notices (e.g., postage receipts or email logs).

• A screenshot or confirmation page from the CMS electronic disclosure filing.

In the event of a DOL audit, having these documents readily available can prevent costly penalties and administrative headaches.

Special Considerations for High Deductible Health Plans (HDHPs)

The rise of High Deductible Health Plans (HDHPs) paired with Health Savings Accounts (HSAs) has complicated the creditability landscape. Because an HDHP generally requires the participant to pay the full cost of prescriptions until the high deductible is met, these plans often struggle to meet the "creditable coverage" standard.

If a plan is non-creditable, it does not mean the organization cannot offer it. It simply means that employees must be informed of this fact so they can make an educated decision. An employee who remains in a non-creditable HDHP after age 65 may face a late enrollment penalty if they eventually transition to a medicare part D plan later in retirement. Furthermore, once an individual enrolls in any part of Medicare, they are no longer eligible to contribute to an HSA, although they can still use existing funds in the account.

The Role of Technology in Compliance

Modern benefits administration systems are increasingly incorporating features to automate the disclosure process. Many platforms can identify participants who are nearing age 65 and automatically trigger the delivery of the required notices.

However, technology is not a "set it and forget it" solution. Benefits administrators must ensure that the data fed into these systems is accurate. For example, if a system is not aware of a covered spouse’s age, it may fail to send the required notice, leaving the organization in a position of non-compliance.

Strategic Benefits Design in a Post-IRA World

With the federal government significantly enhancing the value of its drug benefit, the "gap" between private employer plans and the federal program is narrowing. Some organizations are finding that their legacy plans are now "too generous" compared to the market, while others are struggling to keep up with the new $2,100 out-of-pocket cap.

Strategic planners are now evaluating:

• Transitioning to EGWPs - Moving the risk and administrative burden to a private insurer that specializes in federal compliance.

• Incentivizing Medicare Enrollment - For retirees, it may be more cost-effective for the organization to provide a monthly HRA (Health Reimbursement Arrangement) contribution that the retiree can use to purchase their own supplemental and drug coverage.

• Redesigning Copay Structures - Moving from coinsurance (percentages) to flat copays can sometimes make it easier to pass the "Simplified Determination" tests for creditability.

Summary of Key Regulatory Intersections

Managing pharmacy benefits requires a constant awareness of how private insurance interacts with federal law. The core responsibility lies in transparency, ensuring that every eligible person understands the value of their current plan compared to the federal standard.

By staying ahead of the CMS disclosure deadlines and carefully monitoring the plan’s creditability status as federal standards evolve, organizations can protect both their employees from penalties and themselves from compliance risks. The 2026 landscape is more complex than previous years, but it also offers a more robust benefit to the millions of individuals relying on these programs for their essential medications.

The integration of data-driven decision-making and a proactive compliance calendar remains the most effective defense against the evolving complexities of the federal prescription drug insurance landscape.